Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic defect.
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) expected to beat earnings estimates: Should you buy?
CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...
The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an ...
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...
A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the application of optical genome mapping (OGM) to ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
When Feng Zhang was in his early 30s, he used a set of genes found in bacteria called CRISPR to pioneer a new kind of gene editing tool in human cells. Today, the MIT biochemist is study ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. On January 22, 2026, ...
The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.
How CRISPR and functional genomics are used to establish causality, understand disease mechanisms and guide early drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results